a*1
2 楼
I know they have been bleeding money because their drug did not sell well.
It looks like they will be running out of money very soon and there is no
hope of turning around due to the high cost of making the drug, thus low
profit margin and competition from JNJ of course.
The high cost is due to the specific of their drug and it is quite
complicated to make. One on side, you can argue that it is complicated and
that is why DNDN is losing money, on the other hand, you can argue that
their know-how would make them a target right now, especially with the
current market cap.
It is a high risk one and I don't own the stock. Don't like to gamble anyway
. But I think it is a target to be acquired soon because they will be more
willing to sell and someone would love to have get the know-how and the
infrastructure.
【在 u**********n 的大作中提到】
: 版上这些小药股的pick从何而来？
: 有版友在里面上班？
It looks like they will be running out of money very soon and there is no
hope of turning around due to the high cost of making the drug, thus low
profit margin and competition from JNJ of course.
The high cost is due to the specific of their drug and it is quite
complicated to make. One on side, you can argue that it is complicated and
that is why DNDN is losing money, on the other hand, you can argue that
their know-how would make them a target right now, especially with the
current market cap.
It is a high risk one and I don't own the stock. Don't like to gamble anyway
. But I think it is a target to be acquired soon because they will be more
willing to sell and someone would love to have get the know-how and the
infrastructure.
【在 u**********n 的大作中提到】
: 版上这些小药股的pick从何而来？
: 有版友在里面上班？
相关阅读